Regeneron(REGN) Prnewswire·2025-02-21 10:45Core Viewpoint - A class action securities lawsuit has been filed against Regeneron Pharmaceuticals, alleging securities fraud that affected investors between November 2, 2023, and October 30, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Regeneron made false statements regarding payments made to distributors, which were conditioned on not charging Eylea customers more for credit card usage [2]. - It is alleged that these payments effectively subsidized the prices for customers using credit cards to purchase Eylea, leading to a misleading boost in reported sales [2]. - The complaint further asserts that Regeneron failed to report these payments as price concessions, resulting in an overstatement of the Average Selling Price (ASP) reported to federal agencies, thus violating the False Claims Act [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, indicating a no-cost participation model [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].